Canagliflozin vs Empagliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Canagliflozin · Invokana

Marketed by Johnson & Johnson and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT01032629 · Phase 3 · completed

The trial randomized 4,330 participants to canagliflozin or placebo with quadruple masking and used a hard clinical primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results were discordant across the prespecified comparisons: the 300-mg dose met the endpoint comparison, while the 100-mg dose and combined canagliflozin analysis did not.

Next expected readout: December 2026 · NCT05427084 (registry estimate)

Reported efficacy

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 (Baseline (Day 1) and Week 26); Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (Baseline (Day 1) up to 30 days post last dose at Week 52 (up to Week 56)): Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002). (met)

Result source: NCT03170518

Empagliflozin · Jardiance

Marketed by Boehringer Ingelheim and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT01131676 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial enrolling 7,064 participants. The hard clinical primary endpoint was met: pooled empagliflozin was non-inferior and also statistically superior to placebo for 3-point MACE, with 10.5% versus 12.1% of participants experiencing an event (HR 0.86; p=0.0382).

Next expected readout: November 2026 · NCT05057806 (registry estimate)

Reported efficacy

Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1% (met)

Result source: NCT01131676

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCanagliflozinEmpagliflozin
HbA1c, change-0.4% vs 0.4%−0.8 vs placebo100/300 mg · wk 26 · n 84NCT03170518
41 other results
  • -0.7% vs -0.0% 300 mg · wk 26 · n 229 · Phase 3 · primary NCT01106651
  • -0.4% vs -0.0% 300 mg · wk 26 · n 89 · Phase 3 · primary NCT01064414
  • -1.0% vs -0.3% 300 mg · wk 26 · n 112 · Phase 3 · primary NCT01106690
  • -1.1% vs -0.1% 300 mg · wk 26 · n 152 · Phase 3 · primary NCT01106625
  • -1.0% vs 0.1% 300 mg · wk 26 · n 194 · Phase 3 · primary NCT01081834
  • -1.1% vs -0.5% 300 mg · wk 18 · n 227 · Phase 3 · primary NCT01381900
  • -0.6% vs -0.0% 100 mg · wk 26 · n 239 · Phase 3 · primary NCT01106651
  • -0.3% vs -0.0% 100 mg · wk 26 · n 88 · Phase 3 · primary NCT01064414
  • -0.9% vs -0.3% 100 mg · wk 26 · n 113 · Phase 3 · primary NCT01106690
  • -0.8% vs -0.1% 100 mg · wk 26 · n 155 · Phase 3 · primary NCT01106625
  • -0.8% vs 0.1% 100 mg · wk 26 · n 191 · Phase 3 · primary NCT01081834
  • -1.0% vs -0.5% 100 mg · wk 18 · n 223 · Phase 3 · primary NCT01381900
  • -1.0% vs -0.1% wk 24 · n 70 · Phase 3 · primary NCT02354235
  • -0.9% vs -0.8% 300 mg · wk 52 · n 474 · Phase 3 · primary NCT00968812
  • -1.0% vs -0.7% 300 mg · wk 52 · n 374 · Phase 3 · primary NCT01137812
  • -1.4% vs -1.3% 300 mg · wk 26 · n 234 · Phase 3 · primary NCT01809327
  • -0.9% vs -0.8% 300 mg · wk 26 · n 360 · Phase 3 · primary NCT01106677
  • -0.8% vs -0.8% 100 mg · wk 52 · n 478 · Phase 3 · primary NCT00968812
  • -1.4% vs -1.3% 100 mg · wk 26 · n 230 · Phase 3 · primary NCT01809327
  • -0.8% vs -0.8% 100 mg · wk 26 · n 365 · Phase 3 · primary NCT01106677
  • -1.8% vs -1.3% wk 26 · n 236 · Phase 3 · primary NCT01809327
  • -1.8% vs -1.3% wk 26 · n 235 · Phase 3 · primary NCT01809327
  • -0.3% vs 0.0% 300 mg · wk 338 · n 1352 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.0% 100 mg · wk 338 · n 1392 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.7% 100/300 mg · wk 52 · n 84 · Phase 3 · secondary NCT03170518
  • -0.6% vs 0.1% 100/300 mg · wk 12 · n 84 · Phase 3 · secondary NCT03170518
  • -0.9% vs -0.7% 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 300 mg · wk 104 · n 474 · Phase 3 · secondary NCT00968812
  • -0.7% vs -0.7% 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 100 mg · wk 104 · n 478 · Phase 3 · secondary NCT00968812
  • -0.9% vs -0.2% 300 mg daily · wk 12 · n 60 · Phase 2 · primary NCT00642278
  • -0.8% vs -0.2% 100 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.2% 300 mg twice daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.7% vs -0.2% 200 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.6% vs -0.0% 150 mg Bid · wk 18 · n 91 · Phase 2 · primary NCT01340664
  • -0.5% vs -0.0% 50 mg Bid · wk 18 · n 90 · Phase 2 · primary NCT01340664
  • -0.8% vs -0.2% 50 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.0% wk 26 · n 99 · Phase 4 · primary NCT02025907
  • -1.0% vs 0.1% wk 16 · n 76 · Phase 4 · primary NCT02220920
  • -0.9% vs -1.1% n 76 · Phase 4 · secondary NCT02622113
  • 7.8% vs 8.3% wk 16 · n 15 · Phase 4 · secondary NCT02964585
-0.7% vs -0.2%−0.5 vs placebo10mg · wk 24 · n 217NCT01159600
32 other results
  • -0.8% vs -0.2% 10mg · wk 24 · n 225 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 213 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 216 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 10 mg · wk 24 · n 72 · Phase 3 · primary NCT04233801
  • -0.7% vs 0.1% 10 mg-25 mg · wk 24 · n 78 · Phase 3 · primary NCT02182830
  • -2.8% vs -0.2% 25mg · wk 24 · n 69 · Phase 3 · primary NCT01159600
  • -2.5% vs -0.2% 25mg · wk 24 · n 101 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 25 mg · wk 24 · n 73 · Phase 3 · primary NCT04233801
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.9% vs 0.2% 10 mg/5 mg · wk 24 · n 182 · Phase 3 · primary NCT02453555
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -1.4% vs -1.8% 10 mg qd · wk 24 · n 156 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 12.5 mg Bid + 1000 mg Bid · wk 24 · n 159 · Phase 3 · primary NCT01719003
  • -0.2% vs 0.3% 10 mg, 25 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.4% vs -1.8% 25 mg qd · wk 24 · n 143 · Phase 3 · primary NCT01719003
  • -1.9% vs -1.8% 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 5 mg Bid + 1000 mg Bid · wk 24 · n 151 · Phase 3 · primary NCT01719003
  • -2.0% vs -1.8% 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · primary NCT01719003
  • -0.5% vs 0.3% 10 mg · wk 26 · n 39 · Phase 3 · primary NCT03429543
  • 0.1% vs 0.3% 10 mg, 10-25 mg · wk 26 · n 41 · Phase 3 · primary NCT03429543
  • -1.1% vs 0.1% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -1.1% vs -0.0% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -0.2% vs 0.1% 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -0.6% vs -0.2% 10 mg QD · wk 16 · n 213 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 25 mg QD · wk 16 · n 214 · Phase 2 · primary NCT01649297
  • -0.8% vs -0.2% 12.5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.1% 10 mg · wk 52 · n 64 · Phase 4 · primary NCT04531462
  • -0.9% vs 0% 10 mg · wk 16 · n 86 · Phase 4 · primary NCT02589639
  • -1% vs 0% 25 mg · wk 16 · n 90 · Phase 4 · primary NCT02589639
  • -0.7% vs -0.2% 5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
Body weight, change (kg)-2.9 vs -0.8−2.1 vs placebo300 mg daily · wk 12 · n 62NCT00642278
8 other results
  • -1.5 vs 0.1 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -2.3 vs -0.8 100 mg daily · wk 12 · n 64 · Phase 2 · secondary NCT00642278
  • -1.0 vs 0.1 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -2.9 vs -0.8 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -2.3 vs -0.8 200 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -2.0 vs -0.8 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -3.5 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
  • -6 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
-2.1 vs -0.4−1.7 vs placebo10mg · wk 24 · n 217NCT01159600
18 other results
  • -2.2 vs -0.4 10mg · wk 24 · n 225 · Phase 3 · secondary NCT01159600
  • -2.5 vs -0.4 25mg · wk 24 · n 213 · Phase 3 · secondary NCT01159600
  • -2.4 vs -0.4 25mg · wk 24 · n 216 · Phase 3 · secondary NCT01159600
  • -0.8 vs -0.0 10 mg, 25 mg · wk 26 · n 48 · Phase 3 · secondary NCT03429543
  • -2.0 vs 0.0 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • -2.2 vs -1.0 10 mg-25 mg · wk 24 · n 78 · Phase 3 · secondary NCT02182830
  • -1.3 vs -0.4 25mg · wk 24 · n 69 · Phase 3 · secondary NCT01159600
  • -1.3 vs -0.4 25mg · wk 24 · n 101 · Phase 3 · secondary NCT01159600
  • -1.3 vs 0.0 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 1.3 vs -0.0 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -2.4 vs -1.3 10 mg qd · wk 24 · n 155 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.3 25 mg qd · wk 24 · n 143 · Phase 3 · secondary NCT01719003
  • -3.8 vs -1.3 12.5 mg Bid + 1000 mg Bid · wk 24 · n 160 · Phase 3 · secondary NCT01719003
  • -3.0 vs -1.3 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · secondary NCT01719003
  • -3.5 vs -1.3 5 mg Bid + 1000 mg Bid · wk 24 · n 150 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.3 5 mg Bid + 500 mg Bid · wk 24 · n 155 · Phase 3 · secondary NCT01719003
HbA1c below 7%42.8% vs 43%vs Metformin XR300 mg · wk 26 · n 215NCT01809327
6 other results
  • 38.8% vs 43% 100 mg · wk 26 · n 206 · Phase 3 · secondary NCT01809327
  • 56.8% vs 43% wk 26 · n 213 · Phase 3 · secondary NCT01809327
  • 49.6% vs 43% wk 26 · n 224 · Phase 3 · secondary NCT01809327
  • 57.1% vs 31.5% 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • 47.8% vs 31.5% 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • 32.3% vs 12.2% wk 26 · n 96 · Phase 4 · secondary NCT02025907
34.6% vs 24.5%+10.1 vs placebo10 mg, 25 mg · wk 26 · n 52NCT03429543
3 other results
  • 16.7% vs 8.2% 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • 30.1% vs 8.2% 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • 66.7% vs 24.5% 10 mg, 25 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
Fasting plasma glucose, change-0.6 vs 0.2−0.7 vs placebo300 mg · wk 338 · n 1377NCT01032629
34 other results
  • -0.4 vs 0.2 100 mg · wk 338 · n 1410 · Phase 3 · secondary NCT01032629
  • -1.1 vs 0.4 300 mg · wk 26 · n 229 · Phase 3 · secondary NCT01106651
  • -0.7 vs 0.0 300 mg · wk 26 · n 88 · Phase 3 · secondary NCT01064414
  • -1.8 vs 0.1 300 mg · wk 26 · n 112 · Phase 3 · secondary NCT01106690
  • -1.7 vs 0.2 300 mg · wk 26 · n 152 · Phase 3 · secondary NCT01106625
  • -1.9 vs 0.5 300 mg · wk 26 · n 192 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 300 mg · wk 18 · n 227 · Phase 3 · secondary NCT01381900
  • -1 vs 0.4 100 mg · wk 26 · n 239 · Phase 3 · secondary NCT01106651
  • -0.8 vs 0.0 100 mg · wk 26 · n 90 · Phase 3 · secondary NCT01064414
  • -1.5 vs 0.1 100 mg · wk 26 · n 113 · Phase 3 · secondary NCT01106690
  • -1.0 vs 0.2 100 mg · wk 26 · n 155 · Phase 3 · secondary NCT01106625
  • -1.5 vs 0.5 100 mg · wk 26 · n 188 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 100 mg · wk 18 · n 223 · Phase 3 · secondary NCT01381900
  • -1.9 vs 0.2 wk 24 · n 69 · Phase 3 · secondary NCT02354235
  • -2.1 vs -1.1 300 mg · wk 26 · n 360 · Phase 3 · secondary NCT01106677
  • -1.9 vs -1.0 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -1.7 vs -0.3 300 mg · wk 52 · n 373 · Phase 3 · secondary NCT01137812
  • -1.5 vs -1.1 100 mg · wk 26 · n 365 · Phase 3 · secondary NCT01106677
  • -1.4 vs -1.0 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • 9.7 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • 10.0 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • -1.4 vs 0.2 300 mg daily · wk 12 · n 61 · Phase 2 · secondary NCT00642278
  • -1.3 vs -0.4 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -1.4 vs 0.2 100 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -0.0 vs -0.4 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -1.3 vs 0.2 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -1.5 vs 0.2 200 mg daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -0.9 vs 0.5 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.5 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.2 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -1.6 vs -0.1 wk 26 · n 103 · Phase 4 · secondary NCT02025907
  • -1.9 vs -0.1 wk 16 · n 75 · Phase 4 · secondary NCT02220920
  • -1.8 vs -1.8 n 75 · Phase 4 · secondary NCT02622113
  • 7.9 vs 8.8 wk 16 · n 15 · Phase 4 · secondary NCT02964585
-1.8 vs 0.3−2.1 vs placebo25 mg + 5 mg · wk 24 · n 109NCT01734785
11 other results
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.8 10 mg qd · wk 24 · n 154 · Phase 3 · secondary NCT01719003
  • -1.6 vs -1.8 25 mg qd · wk 24 · n 139 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.8 12.5 mg Bid + 1000 mg Bid · wk 24 · n 158 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.8 12.5 mg Bid + 500 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.6 vs -1.8 5 mg Bid + 1000 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.5 vs -1.8 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · secondary NCT01719003
  • -1.0 vs -0.0 10 mg QD · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.3 vs -0.0 25 mg QD · wk 16 · n 214 · Phase 2 · secondary NCT01649297
  • -1.5 vs -0.0 12.5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.2 vs -0.0 5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
3-point MACE (% with event)—Not posted · NCT0430426110.4% vs 12.1%−1.7 vs placebo10 mg · n 2345NCT01131676
2 other results
  • 10.5% vs 12.1% 25 mg · n 2342 · Phase 3 · primary NCT01131676
  • 10.5% vs 12.1% n 4687 · Phase 3 · primary NCT01131676

HbA1c, change

Canagliflozin
-0.4% vs 0.4%−0.8 vs placebo100/300 mg · wk 26 · n 84NCT03170518
41 other results
  • -0.7% vs -0.0% 300 mg · wk 26 · n 229 · Phase 3 · primary NCT01106651
  • -0.4% vs -0.0% 300 mg · wk 26 · n 89 · Phase 3 · primary NCT01064414
  • -1.0% vs -0.3% 300 mg · wk 26 · n 112 · Phase 3 · primary NCT01106690
  • -1.1% vs -0.1% 300 mg · wk 26 · n 152 · Phase 3 · primary NCT01106625
  • -1.0% vs 0.1% 300 mg · wk 26 · n 194 · Phase 3 · primary NCT01081834
  • -1.1% vs -0.5% 300 mg · wk 18 · n 227 · Phase 3 · primary NCT01381900
  • -0.6% vs -0.0% 100 mg · wk 26 · n 239 · Phase 3 · primary NCT01106651
  • -0.3% vs -0.0% 100 mg · wk 26 · n 88 · Phase 3 · primary NCT01064414
  • -0.9% vs -0.3% 100 mg · wk 26 · n 113 · Phase 3 · primary NCT01106690
  • -0.8% vs -0.1% 100 mg · wk 26 · n 155 · Phase 3 · primary NCT01106625
  • -0.8% vs 0.1% 100 mg · wk 26 · n 191 · Phase 3 · primary NCT01081834
  • -1.0% vs -0.5% 100 mg · wk 18 · n 223 · Phase 3 · primary NCT01381900
  • -1.0% vs -0.1% wk 24 · n 70 · Phase 3 · primary NCT02354235
  • -0.9% vs -0.8% 300 mg · wk 52 · n 474 · Phase 3 · primary NCT00968812
  • -1.0% vs -0.7% 300 mg · wk 52 · n 374 · Phase 3 · primary NCT01137812
  • -1.4% vs -1.3% 300 mg · wk 26 · n 234 · Phase 3 · primary NCT01809327
  • -0.9% vs -0.8% 300 mg · wk 26 · n 360 · Phase 3 · primary NCT01106677
  • -0.8% vs -0.8% 100 mg · wk 52 · n 478 · Phase 3 · primary NCT00968812
  • -1.4% vs -1.3% 100 mg · wk 26 · n 230 · Phase 3 · primary NCT01809327
  • -0.8% vs -0.8% 100 mg · wk 26 · n 365 · Phase 3 · primary NCT01106677
  • -1.8% vs -1.3% wk 26 · n 236 · Phase 3 · primary NCT01809327
  • -1.8% vs -1.3% wk 26 · n 235 · Phase 3 · primary NCT01809327
  • -0.3% vs 0.0% 300 mg · wk 338 · n 1352 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.0% 100 mg · wk 338 · n 1392 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.7% 100/300 mg · wk 52 · n 84 · Phase 3 · secondary NCT03170518
  • -0.6% vs 0.1% 100/300 mg · wk 12 · n 84 · Phase 3 · secondary NCT03170518
  • -0.9% vs -0.7% 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 300 mg · wk 104 · n 474 · Phase 3 · secondary NCT00968812
  • -0.7% vs -0.7% 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 100 mg · wk 104 · n 478 · Phase 3 · secondary NCT00968812
  • -0.9% vs -0.2% 300 mg daily · wk 12 · n 60 · Phase 2 · primary NCT00642278
  • -0.8% vs -0.2% 100 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.2% 300 mg twice daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.7% vs -0.2% 200 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.6% vs -0.0% 150 mg Bid · wk 18 · n 91 · Phase 2 · primary NCT01340664
  • -0.5% vs -0.0% 50 mg Bid · wk 18 · n 90 · Phase 2 · primary NCT01340664
  • -0.8% vs -0.2% 50 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.0% wk 26 · n 99 · Phase 4 · primary NCT02025907
  • -1.0% vs 0.1% wk 16 · n 76 · Phase 4 · primary NCT02220920
  • -0.9% vs -1.1% n 76 · Phase 4 · secondary NCT02622113
  • 7.8% vs 8.3% wk 16 · n 15 · Phase 4 · secondary NCT02964585
Empagliflozin
-0.7% vs -0.2%−0.5 vs placebo10mg · wk 24 · n 217NCT01159600
32 other results
  • -0.8% vs -0.2% 10mg · wk 24 · n 225 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 213 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 216 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 10 mg · wk 24 · n 72 · Phase 3 · primary NCT04233801
  • -0.7% vs 0.1% 10 mg-25 mg · wk 24 · n 78 · Phase 3 · primary NCT02182830
  • -2.8% vs -0.2% 25mg · wk 24 · n 69 · Phase 3 · primary NCT01159600
  • -2.5% vs -0.2% 25mg · wk 24 · n 101 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 25 mg · wk 24 · n 73 · Phase 3 · primary NCT04233801
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.9% vs 0.2% 10 mg/5 mg · wk 24 · n 182 · Phase 3 · primary NCT02453555
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -1.4% vs -1.8% 10 mg qd · wk 24 · n 156 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 12.5 mg Bid + 1000 mg Bid · wk 24 · n 159 · Phase 3 · primary NCT01719003
  • -0.2% vs 0.3% 10 mg, 25 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.4% vs -1.8% 25 mg qd · wk 24 · n 143 · Phase 3 · primary NCT01719003
  • -1.9% vs -1.8% 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 5 mg Bid + 1000 mg Bid · wk 24 · n 151 · Phase 3 · primary NCT01719003
  • -2.0% vs -1.8% 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · primary NCT01719003
  • -0.5% vs 0.3% 10 mg · wk 26 · n 39 · Phase 3 · primary NCT03429543
  • 0.1% vs 0.3% 10 mg, 10-25 mg · wk 26 · n 41 · Phase 3 · primary NCT03429543
  • -1.1% vs 0.1% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -1.1% vs -0.0% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -0.2% vs 0.1% 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -0.6% vs -0.2% 10 mg QD · wk 16 · n 213 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 25 mg QD · wk 16 · n 214 · Phase 2 · primary NCT01649297
  • -0.8% vs -0.2% 12.5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.1% 10 mg · wk 52 · n 64 · Phase 4 · primary NCT04531462
  • -0.9% vs 0% 10 mg · wk 16 · n 86 · Phase 4 · primary NCT02589639
  • -1% vs 0% 25 mg · wk 16 · n 90 · Phase 4 · primary NCT02589639
  • -0.7% vs -0.2% 5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297

Body weight, change (kg)

Canagliflozin
-2.9 vs -0.8−2.1 vs placebo300 mg daily · wk 12 · n 62NCT00642278
8 other results
  • -1.5 vs 0.1 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -2.3 vs -0.8 100 mg daily · wk 12 · n 64 · Phase 2 · secondary NCT00642278
  • -1.0 vs 0.1 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -2.9 vs -0.8 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -2.3 vs -0.8 200 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -2.0 vs -0.8 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -3.5 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
  • -6 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
Empagliflozin
-2.1 vs -0.4−1.7 vs placebo10mg · wk 24 · n 217NCT01159600
18 other results
  • -2.2 vs -0.4 10mg · wk 24 · n 225 · Phase 3 · secondary NCT01159600
  • -2.5 vs -0.4 25mg · wk 24 · n 213 · Phase 3 · secondary NCT01159600
  • -2.4 vs -0.4 25mg · wk 24 · n 216 · Phase 3 · secondary NCT01159600
  • -0.8 vs -0.0 10 mg, 25 mg · wk 26 · n 48 · Phase 3 · secondary NCT03429543
  • -2.0 vs 0.0 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • -2.2 vs -1.0 10 mg-25 mg · wk 24 · n 78 · Phase 3 · secondary NCT02182830
  • -1.3 vs -0.4 25mg · wk 24 · n 69 · Phase 3 · secondary NCT01159600
  • -1.3 vs -0.4 25mg · wk 24 · n 101 · Phase 3 · secondary NCT01159600
  • -1.3 vs 0.0 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 1.3 vs -0.0 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -2.4 vs -1.3 10 mg qd · wk 24 · n 155 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.3 25 mg qd · wk 24 · n 143 · Phase 3 · secondary NCT01719003
  • -3.8 vs -1.3 12.5 mg Bid + 1000 mg Bid · wk 24 · n 160 · Phase 3 · secondary NCT01719003
  • -3.0 vs -1.3 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · secondary NCT01719003
  • -3.5 vs -1.3 5 mg Bid + 1000 mg Bid · wk 24 · n 150 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.3 5 mg Bid + 500 mg Bid · wk 24 · n 155 · Phase 3 · secondary NCT01719003

HbA1c below 7%

Canagliflozin
42.8% vs 43%vs Metformin XR300 mg · wk 26 · n 215NCT01809327
6 other results
  • 38.8% vs 43% 100 mg · wk 26 · n 206 · Phase 3 · secondary NCT01809327
  • 56.8% vs 43% wk 26 · n 213 · Phase 3 · secondary NCT01809327
  • 49.6% vs 43% wk 26 · n 224 · Phase 3 · secondary NCT01809327
  • 57.1% vs 31.5% 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • 47.8% vs 31.5% 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • 32.3% vs 12.2% wk 26 · n 96 · Phase 4 · secondary NCT02025907
Empagliflozin
34.6% vs 24.5%+10.1 vs placebo10 mg, 25 mg · wk 26 · n 52NCT03429543
3 other results
  • 16.7% vs 8.2% 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • 30.1% vs 8.2% 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • 66.7% vs 24.5% 10 mg, 25 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543

Fasting plasma glucose, change

Canagliflozin
-0.6 vs 0.2−0.7 vs placebo300 mg · wk 338 · n 1377NCT01032629
34 other results
  • -0.4 vs 0.2 100 mg · wk 338 · n 1410 · Phase 3 · secondary NCT01032629
  • -1.1 vs 0.4 300 mg · wk 26 · n 229 · Phase 3 · secondary NCT01106651
  • -0.7 vs 0.0 300 mg · wk 26 · n 88 · Phase 3 · secondary NCT01064414
  • -1.8 vs 0.1 300 mg · wk 26 · n 112 · Phase 3 · secondary NCT01106690
  • -1.7 vs 0.2 300 mg · wk 26 · n 152 · Phase 3 · secondary NCT01106625
  • -1.9 vs 0.5 300 mg · wk 26 · n 192 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 300 mg · wk 18 · n 227 · Phase 3 · secondary NCT01381900
  • -1 vs 0.4 100 mg · wk 26 · n 239 · Phase 3 · secondary NCT01106651
  • -0.8 vs 0.0 100 mg · wk 26 · n 90 · Phase 3 · secondary NCT01064414
  • -1.5 vs 0.1 100 mg · wk 26 · n 113 · Phase 3 · secondary NCT01106690
  • -1.0 vs 0.2 100 mg · wk 26 · n 155 · Phase 3 · secondary NCT01106625
  • -1.5 vs 0.5 100 mg · wk 26 · n 188 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 100 mg · wk 18 · n 223 · Phase 3 · secondary NCT01381900
  • -1.9 vs 0.2 wk 24 · n 69 · Phase 3 · secondary NCT02354235
  • -2.1 vs -1.1 300 mg · wk 26 · n 360 · Phase 3 · secondary NCT01106677
  • -1.9 vs -1.0 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -1.7 vs -0.3 300 mg · wk 52 · n 373 · Phase 3 · secondary NCT01137812
  • -1.5 vs -1.1 100 mg · wk 26 · n 365 · Phase 3 · secondary NCT01106677
  • -1.4 vs -1.0 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • 9.7 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • 10.0 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • -1.4 vs 0.2 300 mg daily · wk 12 · n 61 · Phase 2 · secondary NCT00642278
  • -1.3 vs -0.4 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -1.4 vs 0.2 100 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -0.0 vs -0.4 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -1.3 vs 0.2 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -1.5 vs 0.2 200 mg daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -0.9 vs 0.5 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.5 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.2 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -1.6 vs -0.1 wk 26 · n 103 · Phase 4 · secondary NCT02025907
  • -1.9 vs -0.1 wk 16 · n 75 · Phase 4 · secondary NCT02220920
  • -1.8 vs -1.8 n 75 · Phase 4 · secondary NCT02622113
  • 7.9 vs 8.8 wk 16 · n 15 · Phase 4 · secondary NCT02964585
Empagliflozin
-1.8 vs 0.3−2.1 vs placebo25 mg + 5 mg · wk 24 · n 109NCT01734785
11 other results
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.8 10 mg qd · wk 24 · n 154 · Phase 3 · secondary NCT01719003
  • -1.6 vs -1.8 25 mg qd · wk 24 · n 139 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.8 12.5 mg Bid + 1000 mg Bid · wk 24 · n 158 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.8 12.5 mg Bid + 500 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.6 vs -1.8 5 mg Bid + 1000 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.5 vs -1.8 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · secondary NCT01719003
  • -1.0 vs -0.0 10 mg QD · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.3 vs -0.0 25 mg QD · wk 16 · n 214 · Phase 2 · secondary NCT01649297
  • -1.5 vs -0.0 12.5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.2 vs -0.0 5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297

3-point MACE (% with event)

Canagliflozin
—Not posted · NCT04304261
Empagliflozin
10.4% vs 12.1%−1.7 vs placebo10 mg · n 2345NCT01131676
2 other results
  • 10.5% vs 12.1% 25 mg · n 2342 · Phase 3 · primary NCT01131676
  • 10.5% vs 12.1% n 4687 · Phase 3 · primary NCT01131676
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety

Coverage. Canagliflozin: 12 of 12 rows · Empagliflozin: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCanagliflozin
Rows use multiple source trials
Empagliflozin
Rows use multiple source trials
Ambulatory DBP
absolute change · mmHg
-3.27 vs -0.26 placebo mmHg @ 6wk300 mga,b,c,d,e
NCT01939496 · Phase 4 · registry result, not featured evidence
show 1 more dose
-2.18 vs -0.26 placebo mmHg @ 6wk100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
-6.38 vs -1.48 placebo mmHg @ 24wk10 mg-25 mgb,c,d,e
NCT02182830 · Phase 3 · registry result, not featured evidence
Ambulatory SBP
absolute change · mmHg
-7.31 vs -1.26 placebo mmHg @ 6wk300 mga,b,c,d,e
NCT01939496 · Phase 4 · registry result, not featured evidence
show 1 more dose
-4.78 vs -1.26 placebo mmHg @ 6wk100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
-10.33 vs -1.94 placebo mmHg @ 24wk10 mg-25 mgb,c,d,e
NCT02182830 · Phase 3 · registry result, not featured evidence
Body Fat Mass
absolute change · kg
-2.38 vs -0.28 placebo kg @ 26wk300 mga,f,c,d,g
NCT01106651 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.87 vs -0.28 placebo kg @ 26wk100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-1.77 vs 0.08 placebo kg @ 52wk10 mgf,c,d,g
NCT04531462 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose Change mg/dL
absolute change · mg
-11.5 vs 15.3 placebo mg @ 26wk100/300 mgh,d
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-19.48 vs 15.7 placebo mg @ 26wk10 mg, 25 mga,h,d
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 1 more dose
-18.45 vs 15.7 placebo mg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.7% (n=71) @ 52wkc,d
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
1 other source trial
-0.99% (n=153) @ 52wk
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
-0.55% (n=32) @ 52wk10 mga,c,d
NCT02589626 · Phase 4 · registry result, not featured evidence
show 1 more dose
-0.77% (n=33) @ 52wk25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
SBP
absolute change · mmHg
-4.65 vs -0.66 Sitagliptin mmHg @ 52wk300 mga,c,d,i
NCT01106677 · Phase 3 · registry result, not featured evidence
show 1 more dose
-3.53 vs -0.66 Sitagliptin mmHg @ 52wk100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-5.56 vs -1.95 placebo mmHg @ 24wk10 mga,c,d,i
NCT04233801 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.96 vs -1.95 placebo mmHg @ 24wk25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
Seated DBP
absolute change · mmHg
-0.1 vs -0.1 placebo mmHg @ 26wk100/300 mgh,d
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
0.78 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mga,h,d
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 1 more dose
-3.2 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Seated SBP
absolute change · mmHg
0.7 vs 1.4 placebo mmHg @ 26wk100/300 mgh,d
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-0.12 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mga,h,d
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 1 more dose
2.63 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Dropout rate
6.1%300 mgj
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
7%100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
33.4%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
29%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
10.4%100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
0.7%100 mg
NCT02065791 · Phase 3
0%
NCT02964585 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
0%
NCT02920918 · Phase 4 · registry result, not featured evidence
1.2%
NCT01989754 · Phase 4 · registry result, not featured evidence
13.2%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
11.1%
NCT02025907 · Phase 4 · registry result, not featured evidence
3.9%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
3.6%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
5.3%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
4.3%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
9.2%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
11%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
10.5%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
5.1%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
24.6%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
23.7%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
5.3%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
4%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
7.9%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
16.7%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.4%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
8%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
12%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
12.5%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
17.3%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
17.8%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
32.6%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
14%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
8.6%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
12.5%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
7.8%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
10.9%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
13.8%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
7.8%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
6.7%Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
13.3%Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
23.7%10 mgk
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
23.2%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
8%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.7%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
8.7%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
15.9%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
—10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
6.2%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
11.2%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
4.4%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
9.4%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
6.1%25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
2.7%10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
5.5%25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
18.1%10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
7%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
10.2%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
7.5%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5.3%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
10%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
9.9%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
7.7%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
0%25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
12.1%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
8.6%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
6%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
6.4%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
7.8%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—300 mgj
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
—100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.5%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.2%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
—100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
—100 mg
NCT02065791 · Phase 3
—
NCT02964585 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
—
NCT02920918 · Phase 4 · registry result, not featured evidence
—
NCT01989754 · Phase 4 · registry result, not featured evidence
5.3%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
5.6%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
0.9%
NCT02025907 · Phase 4 · registry result, not featured evidence
1.3%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
0%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
4.6%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
2.9%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
2.9%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.3%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
3.4%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
1.7%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
9.7%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.7%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.1%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.7%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.2%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
4.4%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
3.5%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
0.9%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
1.6%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
4.9%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
5.1%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
5.1%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
5.6%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
7.5%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
1.1%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
3.1%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
4.7%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
3.1%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.5%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
—Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
—Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
11.4%10 mgk
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
11.6%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
2.7%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.9%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
3.2%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.9%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
1.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
—10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
4.6%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
5.6%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
3.3%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
3.1%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
3%25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
1.7%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
2.4%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
0%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
3.5%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
2.9%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
2.3%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
—10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
4.8%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
5.9%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
1.8%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
Serious AEs
42.1%300 mgj
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
41.6%100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.7%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.4%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.7%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.9%300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
10.4%100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
33.5%100 mg
NCT02065791 · Phase 3
0%
NCT02964585 · Phase 4 · registry result, not featured evidence
0%300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
17.6%
NCT02920918 · Phase 4 · registry result, not featured evidence
24.6%
NCT01989754 · Phase 4 · registry result, not featured evidence
9.3%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
7%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
1.9%
NCT02025907 · Phase 4 · registry result, not featured evidence
4%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
0%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
1.4%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
2.9%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.7%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.7%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
3%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
18.2%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.4%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
16.6%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
1.8%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.2%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.2%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
23.6%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.1%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
20%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
3.5%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
6.1%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
2.7%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
7.1%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
2.7%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
3.3%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
3.3%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
3.8%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
5.1%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
3.2%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
4.5%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
2.3%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
1%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
2.5%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
5.6%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
6.4%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
3.2%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
0%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
1.6%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.5%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
6.7%Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
0%Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
37.4%10 mgk
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
39%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
4.9%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.2%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
0.5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
1.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
5.4%10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
0%25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
12.3%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
10.5%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
8.9%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
6.3%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
3%25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
13.7%10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
9.6%25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
5.2%25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
0.9%10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
3.7%10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
3.6%25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
4.5%10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
0.6%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
1.8%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
3.8%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.2%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
3.5%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.2%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
0%25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
6.4%Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
7.1%Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
2.3%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
0.9%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
3.2%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
300 mgj
hypoglycaemia 14.6% (placebo 12.1%)
nasopharyngitis 14.1% (placebo 15.3%)
urinary tract infection 11% (placebo 8.9%)
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 59 more results
100 mg
nasopharyngitis 15.6% (placebo 15.3%)
hypoglycaemia 12.5% (placebo 12.1%)
upper respiratory tract infection 10.9% (placebo 11.3%)
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
300 mg
nasopharyngitis 11.3%
diarrhoea 8%
upper respiratory tract infection 7.8%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
300 mg
nasopharyngitis 7.6%
diarrhoea 6.8%
upper respiratory tract infection 5.6%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
nasopharyngitis 9.7%
urinary tract infection 9.1%
upper respiratory tract infection 7.5%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
nasopharyngitis 6.8%
back pain 6%
urinary tract infection 5.4%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
300 mg
urinary tract infection 29.4% (placebo 4.6%)
urinary tract infection 29.4% (placebo 4.6%)
nausea 11.8% (placebo 1.1%)
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
100 mg
headache 11.9% (placebo 3.4%)
headache 11.9% (placebo 3.4%)
nasopharyngitis 11.9% (placebo 5.7%)
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
100 mg
hypoglycaemia 9.7% (placebo 10.3%)
urinary tract infection 9.2% (placebo 8.4%)
hypertension 6.5% (placebo 8.8%)
NCT02065791 · Phase 3
300 mg
fatigue 3.2%
diarrhoea 1.6%
discomfort 1.6%
NCT03267576 · Phase 4 · registry result, not featured evidence
acute kidney injury 17.6%
hypotensive event 11.8%
arrhythmic events 5.9%
NCT02920918 · Phase 4 · registry result, not featured evidence
balanoposthitis 3.2% (placebo 0.9%)
NCT01989754 · Phase 4 · registry result, not featured evidence
blood glucose decreased 40% (placebo 23.9%)
hypoglycaemia 38.7% (placebo 32.8%)
nasopharyngitis 34.7% (placebo 25.4%)
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 33.8%
gastroenteritis 9.9%
hypoglycaemia 9.9%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 5.6% (placebo 5.6%)
back pain 2.8% (placebo 0.9%)
depression 2.8% (placebo 0%)
NCT02025907 · Phase 4 · registry result, not featured evidence
blood glucose decreased 26.7% (placebo 16.9%)
hypoglycaemia 25.3% (placebo 21.1%)
nasopharyngitis 16% (placebo 18.3%)
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
300 mg
pollakiuria 5.4% (placebo 1.8%)
nasopharyngitis 0% (placebo 0%)
NCT01939496 · Phase 4 · registry result, not featured evidence
100 mg
nasopharyngitis 5.3% (placebo 0%)
pollakiuria 1.8% (placebo 1.8%)
NCT01939496 · Phase 4 · registry result, not featured evidence
nasopharyngitis 30.7%
pollakiuria 6.5%
constipation 5.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 18.6% (placebo 16.2%)
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
300 mg
nasopharyngitis 3.8%
upper respiratory tract infection 2.5%
back pain 2.1%
NCT01809327 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 3.8%
glomerular filtration rate decreased 2.5%
influenza 2.5%
NCT01809327 · Phase 3 · registry result, not featured evidence
diarrhoea 4.2%
headache 3%
influenza 3%
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 4.2%
headache 3.8%
influenza 3.4%
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
300 mg
nasopharyngitis 18.6% (placebo 15.2%)
hypoglycaemia 15.3% (placebo 19.8%)
urinary tract infection 14.8% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 9.7% (placebo 19.8%)
nasopharyngitis 8.1% (placebo 15.2%)
urinary tract infection 7.2% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 18.7% (placebo 15.2%)
hypoglycaemia 15.4% (placebo 19.8%)
urinary tract infection 13.3% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 10.4% (placebo 19.8%)
nasopharyngitis 9.5% (placebo 15.2%)
influenza 5.8% (placebo 7.6%)
NCT01106651 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 7.5% (placebo 4%)
upper respiratory tract infection 5.7% (placebo 6.2%)
NCT01381900 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 9% (placebo 4%)
upper respiratory tract infection 3.1% (placebo 6.2%)
NCT01381900 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 11.2% (placebo 4.4%)
nasopharyngitis 7.9% (placebo 11.1%)
urinary tract infection 7.9% (placebo 5.6%)
NCT01064414 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 22.5% (placebo 4.4%)
urinary tract infection 13.5% (placebo 5.6%)
nasopharyngitis 10.1% (placebo 11.1%)
NCT01064414 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 14.4% (placebo 4.4%)
arthralgia 4.4% (placebo 2.2%)
bronchitis 4.4% (placebo 3.3%)
NCT01064414 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 20% (placebo 4.4%)
arthralgia 5.6% (placebo 2.2%)
bronchitis 5.6% (placebo 3.3%)
NCT01064414 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 9.6% (placebo 5.2%)
pollakiuria 6.1% (placebo 0.9%)
arthralgia 5.3% (placebo 1.7%)
NCT01106690 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 13.2% (placebo 5.2%)
arthralgia 7.9% (placebo 1.7%)
urinary tract infection 7.9% (placebo 5.2%)
NCT01106690 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 8% (placebo 6.1%)
back pain 7.1% (placebo 2.6%)
nasopharyngitis 5.3% (placebo 5.2%)
NCT01106690 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 12.4% (placebo 6.1%)
nasopharyngitis 9.7% (placebo 5.2%)
back pain 8.8% (placebo 2.6%)
NCT01106690 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 4.9%
upper respiratory tract infection 4.9%
urinary tract infection 3.5%
NCT01106677 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 6.3%
upper respiratory tract infection 6.3%
urinary tract infection 4.6%
NCT01106677 · Phase 3 · registry result, not featured evidence
100 mg
pollakiuria 5.7%
urinary tract infection 4.9%
nasopharyngitis 4.1%
NCT01106677 · Phase 3 · registry result, not featured evidence
100 mg
urinary tract infection 7.3%
pollakiuria 5.7%
headache 5.2%
NCT01106677 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 6.4% (placebo 3.2%)
hypoglycaemia 5.8% (placebo 3.8%)
nasopharyngitis 5.1% (placebo 2.6%)
NCT01106625 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 7.1% (placebo 3.2%)
hypoglycaemia 7.1% (placebo 3.8%)
nasopharyngitis 5.8% (placebo 2.6%)
NCT01106625 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 10.8% (placebo 6.4%)
hypoglycaemia 7% (placebo 3.8%)
urinary tract infection 5.7% (placebo 5.1%)
NCT01106625 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 13.4% (placebo 6.4%)
hypoglycaemia 8.3% (placebo 3.8%)
urinary tract infection 7.6% (placebo 5.1%)
NCT01106625 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 6.8% (placebo 5.2%)
pain in extremity 6.8% (placebo 0%)
urinary tract infection 4.5% (placebo 4.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 8.1% (placebo 5.2%)
back pain 6.1% (placebo 3.1%)
headache 6.1% (placebo 3.6%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 10.2% (placebo 5.2%)
headache 8.6% (placebo 3.6%)
back pain 7.6% (placebo 3.1%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
urinary tract infection 6.4% (placebo 4.2%)
nasopharyngitis 4.3% (placebo 5.2%)
pain in extremity 2.1% (placebo 0%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
headache 7.2% (placebo 3.6%)
urinary tract infection 7.2% (placebo 4.2%)
nasopharyngitis 5.1% (placebo 5.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
headache 9.7% (placebo 3.6%)
urinary tract infection 8.2% (placebo 4.2%)
nasopharyngitis 7.2% (placebo 5.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 17.5%
nasopharyngitis 8.8%
upper respiratory tract infection 8.8%
NCT01137812 · Phase 3 · registry result, not featured evidence
300 mg daily
headache 4.7% (placebo 3.1%)
nausea 4.7% (placebo 0%)
abdominal pain upper 3.1% (placebo 1.5%)
NCT00642278 · Phase 2 · registry result, not featured evidence
100 mg daily
headache 7.8% (placebo 3.1%)
urinary tract infection 3.1% (placebo 6.2%)
vulvovaginal mycotic infection 3.1% (placebo 0%)
NCT00642278 · Phase 2 · registry result, not featured evidence
300 mg twice daily
nausea 7.8% (placebo 0%)
abdominal pain upper 6.3% (placebo 1.5%)
urinary tract infection 4.7% (placebo 6.2%)
NCT00642278 · Phase 2 · registry result, not featured evidence
200 mg daily
urinary tract infection 9.2% (placebo 6.2%)
vulvovaginal mycotic infection 6.2% (placebo 0%)
headache 3.1% (placebo 3.1%)
NCT00642278 · Phase 2 · registry result, not featured evidence
50 mg daily
nasopharyngitis 7.8% (placebo 3.1%)
vulvovaginal mycotic infection 6.3% (placebo 0%)
nausea 4.7% (placebo 0%)
NCT00642278 · Phase 2 · registry result, not featured evidence
urinary frequency increased 86.7%
dry mouth 26.7%
light-headedness/dizziness 26.7%
NCT02324842 · Phase na · registry result, not featured evidence
nausea 53.3%
dry mouth 40%
constipation 33.3%
NCT02324842 · Phase na · registry result, not featured evidence · combination
10 mgk
hypoglycaemia 29.6% (placebo 29.4%)
urinary tract infection 14.5% (placebo 14.7%)
hyperglycaemia 9.3% (placebo 18.1%)
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 37 more results
25 mg
hypoglycaemia 28.7% (placebo 29.4%)
urinary tract infection 14.4% (placebo 14.7%)
nasopharyngitis 9.4% (placebo 9.3%)
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
10mg
hypoglycaemia 15.6% (placebo 9.8%)
urinary tract infection 9.4% (placebo 6.7%)
nasopharyngitis 8% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
10mg
nasopharyngitis 5.5% (placebo 4.9%)
urinary tract infection 4.1% (placebo 6.7%)
hyperglycaemia 2.3% (placebo 12.4%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
25mg
hypoglycaemia 12.9% (placebo 9.8%)
urinary tract infection 6.9% (placebo 6.7%)
nasopharyngitis 6% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
25mg
hypoglycaemia 8.9% (placebo 9.8%)
hyperglycaemia 7.9% (placebo 12.4%)
nasopharyngitis 5% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
25mg
nasopharyngitis 7% (placebo 4.9%)
upper respiratory tract infections 4.2% (placebo 5.3%)
urinary tract infection 4.2% (placebo 6.7%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
25mg
nasopharyngitis 7.2% (placebo 4.9%)
urinary tract infection 7.2% (placebo 6.7%)
diarrhoea 5.8% (placebo 0%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
10 mg
headache 16.2% (placebo 15.5%)
hypoglycaemia 16.2% (placebo 12.1%)
vitamin d deficiency 13.5% (placebo 13.8%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
25 mg
hypoglycaemia 17.2% (placebo 12.1%)
blood ketone body increased 10.3% (placebo 3.4%)
headache 10.3% (placebo 15.5%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
10 mg
constipation 10.8% (placebo 4.7%)
pyrexia 6.2% (placebo 4.7%)
nasopharyngitis 4.6% (placebo 6.3%)
NCT04531462 · Phase 4 · registry result, not featured evidence
10 mg
nasopharyngitis 34.9% (placebo 31.1%)
hypoglycaemia 27.9% (placebo 21.1%)
pollakiuria 10.5% (placebo 2.2%)
NCT02589639 · Phase 4 · registry result, not featured evidence
25 mg
hypoglycaemia 27.8% (placebo 21.1%)
nasopharyngitis 26.7% (placebo 31.1%)
pollakiuria 10% (placebo 2.2%)
NCT02589639 · Phase 4 · registry result, not featured evidence
10 mg
viral upper respiratory tract infection 31.3%
fall 3.1%
influenza 0%
NCT02589626 · Phase 4 · registry result, not featured evidence
25mg
viral upper respiratory tract infection 33.3%
influenza 9.1%
fall 6.1%
NCT02589626 · Phase 4 · registry result, not featured evidence
10 mg
hypoglycaemia 20.5% (placebo 15.1%)
urinary tract infection 8.2% (placebo 13.7%)
hyperlipidaemia 5.5% (placebo 2.7%)
NCT04233801 · Phase 3 · registry result, not featured evidence
25 mg
hypoglycaemia 15.1% (placebo 15.1%)
urinary tract infection 8.2% (placebo 13.7%)
hyperlipidaemia 5.5% (placebo 2.7%)
NCT04233801 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
viral upper respiratory tract infection 26.7% (placebo 22.2%)
blood ketone body increased 13.8% (placebo 10.2%)
back pain 6% (placebo 2.8%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
viral upper respiratory tract infection 15% (placebo 22.2%)
back pain 2.8% (placebo 2.8%)
contusion 2.8% (placebo 0.9%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg-25 mg
lipase increased 7.5% (placebo 3.9%)
cough 6.3% (placebo 1.3%)
upper respiratory tract infection 2.5% (placebo 5.2%)
NCT02182830 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
nasopharyngitis 3.6% (placebo 7.3%)
lipase increased 2.7% (placebo 5.5%)
urinary tract infection 2.7% (placebo 6.4%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
urinary tract infection 7.1% (placebo 6.4%)
nasopharyngitis 4.5% (placebo 7.3%)
lipase increased 3.6% (placebo 5.5%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg qd
dyslipidaemia 8.7%
urinary tract infection 7%
upper respiratory tract infection 2.9%
NCT01719003 · Phase 3 · registry result, not featured evidence
25 mg qd
urinary tract infection 7.8%
dyslipidaemia 6.6%
upper respiratory tract infection 4.2%
NCT01719003 · Phase 3 · registry result, not featured evidence
12.5 mg Bid + 1000 mg Bid
diarrhoea 7.5%
dizziness 5.7%
gastritis 5.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
12.5 mg Bid + 1000 mg Bid
urinary tract infection 10.6%
diarrhoea 7.1%
dyslipidaemia 4.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
12.5 mg Bid + 500 mg Bid
urinary tract infection 10%
dizziness 5.3%
diarrhoea 3.5%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5 mg Bid + 1000 mg Bid
urinary tract infection 7%
dyslipidaemia 4.7%
upper respiratory tract infection 4.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5 mg Bid + 500 mg Bid
dyslipidaemia 8.9%
diarrhoea 5.3%
urinary tract infection 5.3%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
10 mg
nasopharyngitis 10% (placebo 4.8%)
anal inflammation 0% (placebo 0%)
bartholinitis 0% (placebo 0%)
NCT01947855 · Phase 3 · registry result, not featured evidence
25 mg
anal inflammation 5.3% (placebo 0%)
bartholinitis 5.3% (placebo 0%)
pollakiuria 5.3% (placebo 0%)
NCT01947855 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.1%
glomerular filtration rate decreased 3.8%
hyperkalaemia 3.8%
NCT05254002 · Phase 2 · registry result, not featured evidence
hyperkalaemia 9.3%
glomerular filtration rate decreased 6.3%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
25 mg
ketosis 19.4% (placebo 3.3%)
fatigue 9.7% (placebo 0%)
headache 9.7% (placebo 10%)
NCT02632747 · Phase 2 · registry result, not featured evidence
10 mg QD
urinary tract infection 6.8% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
25 mg QD
urinary tract infection 4.6% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
12.5 mg BID
urinary tract infection 4.6% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
5 mg BID
urinary tract infection 3.7% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 4 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 6 weeks versus 24 weeks.
  6. fTrial phases differ: Phase 3 versus Phase 4.
  7. gAssessment timepoints differ: 26 weeks versus 52 weeks.
  8. hPopulation context differs: baseline_threshold differs (hba1c<=11, hba1c>=6.5 versus hba1c<=10.5, hba1c>=6.5).
  9. iAssessment timepoints differ: 52 weeks versus 24 weeks.
  10. jPopulation comparability has not been reviewed for 65 of these studies.
  11. kPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Canagliflozin

Albuminuria Progression 18.3% (n=1298) vs 24% (n=1286) placebo @ 338wk300 mg
responder rate · % of participants
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
20.2% (n=1334) vs 24% (n=1286) placebo @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
UACR Change 24.47 vs 29.3 placebo mg @ 338wk300 mg
absolute change · mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
25.5 vs 29.3 placebo mg @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
33.97 vs 43.41 placebo mg @ 16wk
NCT02964585 · Phase 4 · registry result, not featured evidence
eGFR -3.98 vs -5.23 placebo mL @ 338wk300 mg
absolute change · mL
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
-3.55 vs -5.23 placebo mL @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
79.9 vs 88.33 placebo mL @ 16wk
NCT02964585 · Phase 4 · registry result, not featured evidence
Weight -4.12% (n=1388) vs -0.5% (n=1398) placebo @ 338wk300 mg
percent change · % of baseline
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 33 more results
-4.7% (n=480) vs 1% (n=478) Glimepiride @ 52wk300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.6% (n=84) vs 0% (n=85) placebo @ 26wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-0.5% (n=84) vs 0.4% (n=85) placebo @ 52wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-3.9% (n=236) vs -2.1% (n=237) Metformin XR @ 26wk300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
-3.1% (n=229) vs -0.1% (n=234) placebo @ 26wk300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-3.8% (n=112) vs -0.1% (n=114) placebo @ 26wk300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-4.2% (n=360) vs -1.2% (n=355) Sitagliptin @ 26wk300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-4.2% (n=360) vs -1.3% (n=355) Sitagliptin @ 52wk300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-2.6% (n=154) vs -0.7% (n=150) placebo @ 26wk300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
-3.9% (n=194) vs -0.6% (n=190) placebo @ 26wk300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
-2.5% (n=375) vs 0.3% (n=367) Sitagliptin @ 52wk300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
-3.4% (n=62) vs -1.1% (n=62) placebo @ 12wk300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-3.47% (n=1415) vs -0.5% (n=1398) placebo @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-4.2% (n=479) vs 1% (n=478) Glimepiride @ 52wk100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
-3% (n=236) vs -2.1% (n=237) Metformin XR @ 26wk100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
-2.4% (n=240) vs -0.1% (n=234) placebo @ 26wk100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-2.8% (n=113) vs -0.1% (n=114) placebo @ 26wk100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-3.7% (n=365) vs -1.2% (n=355) Sitagliptin @ 26wk100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-3.8% (n=365) vs -1.3% (n=355) Sitagliptin @ 52wk100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-2.1% (n=156) vs -0.7% (n=150) placebo @ 26wk100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
-2.8% (n=192) vs -0.6% (n=190) placebo @ 26wk100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
-2.6% (n=64) vs -1.1% (n=62) placebo @ 12wk100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-3.4% (n=62) vs -1.1% (n=62) placebo @ 12wk300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-4.2% (n=236) vs -2.1% (n=237) Metformin XR @ 26wk
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
-2.7% (n=63) vs -1.1% (n=62) placebo @ 12wk200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-3.2% (n=91) vs -0.6% (n=92) placebo @ 18wk150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
-3.5% (n=237) vs -2.1% (n=237) Metformin XR @ 26wk
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
-2.8% (n=90) vs -0.6% (n=92) placebo @ 18wk50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
-2.3% (n=63) vs -1.1% (n=62) placebo @ 12wk50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-2.14% (n=75) vs -1.4% (n=65) placebo
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
-3.35% (n=103) vs -1.6% (n=104) placebo @ 26wk
NCT02025907 · Phase 4 · registry result, not featured evidence
-2.13% (n=75) vs 0.24% (n=70) placebo @ 16wk
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
-3.32% (n=69) vs -0.99% (n=67) placebo @ 24wk
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
HbA1c Less Than 7 5 64.9% (n=84) vs 40% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <7.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7 5 69% (n=84) vs 29.3% (n=87) placebo @ 52wk100/300 mg
responder rate · % of participants
Week 52: HbA1c <7.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 51.9% (n=84) vs 27.5% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <7%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 54.9% (n=84) vs 22.7% (n=87) placebo @ 52wk100/300 mg
responder rate · % of participants
Week 52: HbA1c <7%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 6 5 41.6% (n=84) vs 11.3% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <6.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 6 5 36.6% (n=84) vs 12% (n=87) placebo @ 52wk100/300 mg
responder rate · % of participants
Week 52: HbA1c <6.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
Glycemic Rescue 11.9% (n=84) vs 46% (n=87) placebo100/300 mg
responder rate · % of participants
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
BMI -0.8 vs -0.4 placebo kg @ 26wk100/300 mg
absolute change · kg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
-0.7 vs -0.5 placebo kg @ 52wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
30.53 vs 34.64 placebo kg @ 16wk
NCT02964585 · Phase 4 · registry result, not featured evidence

+ 31 further endpoints in the CSV export.

Empagliflozin

MACE 3-point Composite 10.4% (n=2345) vs 12.1% (n=2333) placebo10 mg
event count · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
10.5% (n=2342) vs 12.1% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
10.5% (n=4687) vs 12.1% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
MACE 4-point Composite 12.8% (n=2345) vs 14.3% (n=2333) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
12.8% (n=2342) vs 14.3% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
12.8% (n=4687) vs 14.3% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Silent MI 1.6% (n=1174) vs 1.2% (n=1211) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
1.6% (n=1204) vs 1.2% (n=1211) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
1.6% (n=2378) vs 1.2% (n=1211) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
HF Hospitalization 2.6% (n=2345) vs 4.1% (n=2333) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
2.8% (n=2342) vs 4.1% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
2.7% (n=4687) vs 4.1% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
New Onset Albuminuria 51.5% (n=1403) vs 51.2% (n=1374) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
51.5% (n=1376) vs 51.2% (n=1374) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
51.5% (n=2779) vs 51.2% (n=1374) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
New Onset Macroalbuminuria 10.9% (n=2037) vs 16.2% (n=2033) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
11.5% (n=2054) vs 16.2% (n=2033) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
11.2% (n=4091) vs 16.2% (n=2033) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Composite Microvascular Outcome 13.9% (n=2057) vs 20.5% (n=2068) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
14.1% (n=2075) vs 20.5% (n=2068) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
14% (n=4132) vs 20.5% (n=2068) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Daily Plasma Glucose Change mg/dL -0.54 vs -0.11 placebo mmol/L @ 24wk10mg
absolute change · mmol/L
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -9.64 mg/dL as posted
show 5 more results
-0.56 vs -0.11 placebo mmol/L @ 24wk*10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -10.01 mg/dL as posted
-0.8 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.36 mg/dL as posted
-1.97 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -35.47 mg/dL as posted
-0.72 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -13.06 mg/dL as posted
-1.63 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -29.34 mg/dL as posted
Treatment Failure 50% (n=6) vs 60% (n=5) placebo @ 26wk10 mg, 25 mg
responder rate · % of participants
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Time to Treatment Failure 5.5 vs 2.16 placebo months10 mg, 25 mg
time to event · months
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 · converted to months from 167.333 days as posted
HbA1c Less Than 6 5 21.2% (n=52) vs 9.4% (n=53) placebo @ 26wk10 mg, 25 mg
responder rate · % of participants
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 1 more result
16.7% (n=6) vs 9.4% (n=53) placebo @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Muscle Mass -1.57 vs -0.96 placebo kg @ 52wk10 mg
absolute change · kg
NCT04531462 · Phase 4 · registry result, not featured evidence

+ 13 further endpoints in the CSV export.

Chronic Kidney Disease

Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline

Canagliflozin · Invokana

Marketed by Johnson & Johnson and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT02065791 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 4,401 participants with type 2 diabetes and diabetic nephropathy. Canagliflozin significantly lowered the rate of the composite renal/cardiovascular endpoint (kidney failure, doubling of creatinine, or renal/CV death) compared with placebo, with a hazard ratio of 0.70.

Next expected readout: December 2026 · NCT05507892 (registry estimate)

Reported efficacy

Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029) (met)

Result source: NCT03436693

Empagliflozin · Jardiance

Marketed by Boehringer Ingelheim and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT03594110 · Phase 3 · completed

Patients with chronic kidney disease (6,609) were randomly assigned to empagliflozin 10 mg or matching placebo under double-blind conditions. The primary outcome was a composite of kidney disease progression or cardiovascular death. It was registered for the active trial and again for the whole study, which added up to 2 years of follow-up after the study drug stopped. Empagliflozin reduced the outcome in the active trial (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001) and over the whole study (hazard ratio 0.79, 95% CI 0.72 to 0.87). The figures come from the two published papers (N Engl J Med 2023 and 2025).

Next expected readout: December 2026 · NCT05786443 (registry estimate)

Reported efficacy

Time to first kidney disease progression or cardiovascular death (adjudicated): in the interventional part (up to 1136 days) and over the overall study including post-trial follow-up (up to 1869 days): Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met. (met)

Result source: NCT03594110

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCanagliflozinEmpagliflozin
Kidney composite outcome—Not reported6.1% vs 8.1%−2 vs placebo10 mg · n 3304NCT03594110
1 other result
  • 7.5% vs 8.9% 10 mg · n 3304 · Phase 3 · secondary NCT03594110
UACR, % change0.6% vs 1.2%−0.6 vs placebo100mg · wk 104 · n 124NCT03436693-39.1% vs -2.6%−36.5 vs placebo10 mg · wk 14 · n 61NCT05182840
5 other results
  • -36.6% vs -2.6% 20 mg · wk 14 · n 59 · Phase 2 · primary NCT05182840
  • -22.4% vs -2.6% 3 mg · wk 14 · n 65 · Phase 2 · primary NCT05182840
  • -19% vs -10.6% 10 mg + 3 mg · wk 14 · n 63 · Phase 2 · primary NCT05182840
  • -45.9% vs -10.6% 10 mg + 10 mg · wk 14 · n 60 · Phase 2 · primary NCT05182840
  • -40.3% vs -10.6% 10 mg + 20 mg · wk 14 · n 62 · Phase 2 · primary NCT05182840
eGFR slope—Not reported—Not posted · NCT05373680
Haemoglobin, change—Not reported—Not posted · NCT05373680

Kidney composite outcome

Canagliflozin
—Not reported
Empagliflozin
6.1% vs 8.1%−2 vs placebo10 mg · n 3304NCT03594110
1 other result
  • 7.5% vs 8.9% 10 mg · n 3304 · Phase 3 · secondary NCT03594110

UACR, % change

Canagliflozin
0.6% vs 1.2%−0.6 vs placebo100mg · wk 104 · n 124NCT03436693
Empagliflozin
-39.1% vs -2.6%−36.5 vs placebo10 mg · wk 14 · n 61NCT05182840
5 other results
  • -36.6% vs -2.6% 20 mg · wk 14 · n 59 · Phase 2 · primary NCT05182840
  • -22.4% vs -2.6% 3 mg · wk 14 · n 65 · Phase 2 · primary NCT05182840
  • -19% vs -10.6% 10 mg + 3 mg · wk 14 · n 63 · Phase 2 · primary NCT05182840
  • -45.9% vs -10.6% 10 mg + 10 mg · wk 14 · n 60 · Phase 2 · primary NCT05182840
  • -40.3% vs -10.6% 10 mg + 20 mg · wk 14 · n 62 · Phase 2 · primary NCT05182840

eGFR slope

Canagliflozin
—Not reported
Empagliflozin
—Not posted · NCT05373680

Haemoglobin, change

Canagliflozin
—Not reported
Empagliflozin
—Not posted · NCT05373680
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Canagliflozin: 4 of 4 rows · Empagliflozin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCanagliflozinEmpagliflozin
Dropout rate
0.7%100 mga
NCT02065791 · Phase 3
show 1 more result
19.5%100mg
NCT03436693 · Phase 3
22.9%10 mga
NCT03594110 · Phase 3
show 9 more results
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
12.1%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—100 mga
NCT02065791 · Phase 3
show 1 more result
14.3%100mg
NCT03436693 · Phase 3
7.2%10 mga
NCT03594110 · Phase 3
show 9 more results
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
4.8%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Serious AEs
33.5%100 mga
NCT02065791 · Phase 3
show 1 more result
27.9%100mg
NCT03436693 · Phase 3
33%10 mga
NCT03594110 · Phase 3
show 9 more results
6.4%Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
7.1%Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
5.6%10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
8.3%20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
9.6%10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
6.8%10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
5.3%10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
4.3%3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mga
hypoglycaemia 9.7% (placebo 10.3%)
urinary tract infection 9.2% (placebo 8.4%)
hypertension 6.5% (placebo 8.8%)
NCT02065791 · Phase 3
show 1 more result
100mg
nasopharyngitis 35.1% (placebo 37%)
hypoglycaemia 21.4% (placebo 20.8%)
blood glucose decreased 17.5% (placebo 14.9%)
NCT03436693 · Phase 3
10 mga
gout 6.9% (placebo 7.9%)
NCT03594110 · Phase 3
show 8 more results
nasopharyngitis 4.1%
glomerular filtration rate decreased 3.8%
hyperkalaemia 3.8%
NCT05254002 · Phase 2 · registry result, not featured evidence
hyperkalaemia 9.3%
glomerular filtration rate decreased 6.3%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
10 mg
glomerular filtration rate decreased 9.9% (placebo 4.1%)
hyperkalaemia 9.9% (placebo 5.5%)
cortisol decreased 5.6% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence
20 mg
hyperkalaemia 23.6% (placebo 5.5%)
glomerular filtration rate decreased 8.3% (placebo 4.1%)
upper respiratory tract infection 4.2% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence
10 mg + 10 mg
hyperkalaemia 15.1% (placebo 5.5%)
glomerular filtration rate decreased 11% (placebo 4.1%)
hypotension 5.5% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
10 mg + 20 mg
glomerular filtration rate decreased 9.5% (placebo 4.1%)
hyperkalaemia 9.5% (placebo 5.5%)
upper respiratory tract infection 5.4% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
10 mg + 3 mg
hyperkalaemia 6.6% (placebo 5.5%)
glomerular filtration rate decreased 5.3% (placebo 4.1%)
cortisol decreased 2.6% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
3 mg
hyperkalaemia 11.4% (placebo 5.5%)
cortisol decreased 4.3% (placebo 0%)
upper respiratory tract infection 2.9% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Canagliflozin

eGFR 30% Decline 18.2% (n=154) vs 29.5% (n=154) placebo @ 104wk100mg
responder rate · % of participants
NCT03436693 · Phase 3
eGFR 40% Decline 10.1% (n=154) vs 13.9% (n=154) placebo @ 104wk100mg
responder rate · % of participants
NCT03436693 · Phase 3
eGFR Change mL/Min/1.73 m2 -10.39 vs -11.49 placebo mL @ 104wk100mg
absolute change · mL
NCT03436693 · Phase 3

Empagliflozin

Time to Cardio-renal Composite Endpoint 6.85% (n=3304) vs 8.96% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
show 1 more result
8.36% (n=3304) vs 9.99% (n=3305) placebo10 mg
NCT03594110 · Phase 3
Time to Cardiovascular Composite Endpoint 2.04% (n=3304) vs 2.39% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Overall Survival 0.1% vs 0.1% placebo10 mg
time to event · count
NCT03594110 · Phase 3
Time to Composite Renal Endpoint 6.09% (n=3304) vs 8.09% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
show 1 more result
7.52% (n=3304) vs 8.95% (n=3305) placebo10 mg
NCT03594110 · Phase 3
Time to CV Death 0.91% (n=3304) vs 1.08% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to CV Death or ESKD 2.55% (n=3304) vs 3.45% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to Death or ESKD 5.13% (n=3304) vs 6.08% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to ESKD 2.72% (n=3304) vs 3.49% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
UACR 0.483 vs 0.708 Empagliflozin ratio @ 25.7wk
ratio to baseline · ratio
NCT05254002 · Phase 2 · registry result, not featured evidence
show 2 more results
0.483 vs 0.683 Finerenone ratio @ 25.7wk
NCT05254002 · Phase 2 · registry result, not featured evidence
0.818 vs 0.853 Finerenone ratio @ 30wk
NCT05254002 · Phase 2 · registry result, not featured evidence
eGFR 30% Decline 6.3% (n=268) vs 3.8% (n=264) Finerenone @ 4.3wk
event count · % of participants
NCT05254002 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted
UACR -0.496 vs -0.027 placebo mg @ 14wk10 mg
absolute change · mg
NCT05182840 · Phase 2 · registry result, not featured evidence
show 5 more results
-0.455 vs -0.027 placebo mg @ 14wk20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
-0.21 vs -0.112 Empagliflozin mg @ 14wk10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.614 vs -0.112 Empagliflozin mg @ 14wk10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.516 vs -0.112 Empagliflozin mg @ 14wk10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.254 vs -0.027 placebo mg @ 14wk3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
UACR 30 50.8% (n=61) vs 14.5% (n=69) placebo @ 14wk10 mg
responder rate · % of participants
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 31 Participants as posted
show 23 more results
45.9% (n=61) vs 13% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted
50.8% (n=61) vs 20.3% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 31 Participants as posted
50% (n=56) vs 13.6% (n=66) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted
50.8% (n=59) vs 14.5% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 30 Participants as posted
42.4% (n=59) vs 13% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted
54.2% (n=59) vs 20.3% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
50% (n=50) vs 13.6% (n=66) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted
33.3% (n=63) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 21 Participants as posted
70% (n=60) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 42 Participants as posted
58.1% (n=62) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 36 Participants as posted
33.3% (n=63) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 21 Participants as posted
56.7% (n=60) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
51.6% (n=62) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 32 Participants as posted
36.5% (n=63) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 23 Participants as posted
60% (n=60) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 36 Participants as posted
66.1% (n=62) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
33.3% (n=63) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 21 Participants as posted
66.7% (n=51) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
57.1% (n=56) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 32 Participants as posted
29.2% (n=65) vs 14.5% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted
29.2% (n=65) vs 13% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted
33.8% (n=65) vs 20.3% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
31.1% (n=61) vs 13.6% (n=66) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · Empagliflozin's landscape